Our pre-clinical studies, together with the bladder cancer cells presented here, suggest possible clinical uses of fascin inhibitors as new bladder cancer treatments in combination with chemotherapies or checkpoint immunotherapies. The gene discussed is FSCN1; the disease is urinary bladder cancer.